NACDS offers solutions to congressional committee examining health care costs
WASHINGTON – The National Association of Chain Drug Stores (NACDS) is calling on the U.S.
Pharmacy
Home medical device challenges for 2024
One of the nation’s largest nonprofit patient safety organizations has named challenges for patients and caregivers using medical devices at home as the most pressing health technology safety hazard for 2024.
Cardinal Health to acquire Specialty Networks
Cardinal Health announced on Wednesday that it has entered into a definitive agreement to acquire Specialty Networks, a technology-enabled multi-specialty group purchasing and practice enhancement organization for $1.2B in cash.
Hy-Vee becomes joint owner of Exemplar Care
Hy-Vee Inc. has become a joint owner of the medical clinic operator Exemplar Care as it works to bring more affordable primary care and urgent care services to Iowa patients and employers.
NACDS’ Steve Anderson to speak at HHS Food Is Medicine Summit
On Wednesday, January 31, the U.S. Department of Health and Human Services (HHS) is set to hold its first ever Food is Medicine Summit where NACDS president and CEO Steven Anderson will speak.
Aurobindo gets FDA approval for lacosamide oral solution
EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application lacosamide oral solution USP, 10mg/mLs.
Aurobindo receives FDA approval for isotretinoin capsule
EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application isotretinoin capsules.
The Ohio State University Wexner Medical Center and CVS Accountable Care collaborate to improve Medicare beneficiary care
COLUMBUS, Ohio – The Ohio State University Wexner Medical Center and CVS Accountable Care, part of CVS Health, announced the creation of an accountable care organization (ACO) to improve the quality of care for Medicare beneficiaries by Ohio State providers in central Ohio.
Lupin receives tentative approval from FDA for rivaroxaban tablets
Lupin announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg, and 20 mg, to market a generic equivalent of Xarelto Tablets, 2.
Fourteen U.S. senators urge FTC to complete 18-month study into PBM middlemen
NACDS is applauding U.S. Senators Chuck Grassley (R-IA) and Maria Cantwell (D-WA) for their continued commitment to delivering meaningful PBM reform. On January 23, Sens. Grassley and Cantwell — joined by Sens.
AAM requests federal injunction to block Illinois’ unconstitutional drug price law
WASHINGTON – This week the Association for Accessible Medicines (AAM), the trade association representing America’s manufacturers of generic and biosimilar medicines, filed a lawsuit against Illinois Attorney General Kwame Raoul, requesting that a Federal district court in Illinois enjoin the Attorn
Keren Haruvi named association chair for AAM board
The Board of Directors of the Association for Accessible Medicines (AAM) has named as its new Chairperson, Keren Haruvi, President of Sandoz North America, who was elected for a one-year term.
Liviniti and Mark Cuban Cost Plus Drug Company partner
NATCHITOCHES, La. – Long recognized as a PBM leader in transparency and prescription drug savings, Liviniti announced the addition of the Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) to its network of pharmacies.
Walgreens looking at selling Shields Health specialty pharmacy business
According to published reports, Walgreens Boots Alliance (WBA) is exploring options, including the sale of Shields Health Solutions, a specialty pharmacy business it purchased three years ago.
Veteran’s Health Administration joins Pulse by NABP
The Veteran’s Health Administration (VHA) has joined Pulse by NABP, the National Association of Boards of Pharmacy’s (NABP’s) new digital platform that will bring visibility to the drug supply chain and protect patients from counterfeit or substandard prescription medications.
The Inflation Reduction Act’s impact on biosimilars
The Inflation Reduction Act (IRA), which was signed into law in August of 2022, announced several provisions on prescription drugs, with the aim of lowering the burden on people and reducing federal spending on drugs.